Lung Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Lung Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma [Phase 2, Phase 3]
A clinical trial update on adjuvant chemotherapy for high-risk stage I lung adenocarcinoma across Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) [Phase 2]
Phase II trial update (VISION) evaluating Tepotinib in advanced non-small cell lung cancer with MET alterations; results were posted in 2023…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 clinical trial update evaluating bevacizumab after chemoradiotherapy for locally advanced lung adenocarcinoma is completed.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 trial investigating serplulimab combined with an anti-VEGF antibody in advanced lung adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant afatinib for potentially resectable stage III EGFR mutation-positive lung adenocarcinoma has c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating camrelizumab in combination with apatinib and albumin paclitaxel for advanced lung adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib [Phase 1, Phase 2]
A Phase 1/2 trial evaluating trametinib with erlotinib in EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib has complet…
-
CLINICAL_TRIALS trial_result · 2022-01-24Clinical Trial Update: Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect [Phase 3]
A Phase 3 clinical trial evaluating prophylactic traditional Chinese medicine (TCM) to mitigate dermatological adverse effects related to EG…
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas [Phase 1, Phase 2]
Clinical trial update for ctDNA-MRD based adjuvant targeted therapy in EGFR-positive stage I lung adenocarcinoma (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC [Phase 2]
Phase 2 trial evaluating nivolumab combined with radiotherapy in advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm [Phase 2]
Phase 2 trial investigating postoperative pembrolizumab for patients with solid predominant or micropapillary lung adenocarcinoma, stage I, …
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma [Phase 2]
Phase 2 trial investigating metformin with or without a fasting-mimicking diet for Advanced LKB1-inactive Lung Adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2020-05-01Clinical Trial Update: Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection [Phase 2]
A Phase 2 clinical trial evaluating outcomes after omitting daily routine chest radiographs following pulmonary resection.
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung [Phase 1, Phase 2]
Phase 1/2 study evaluating JNJ-64041757 plus nivolumab versus nivolumab alone in advanced lung adenocarcinoma; the trial was terminated and …
-
CLINICAL_TRIALS trial_result · 2019-10-15Clinical Trial Update: EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression [Phase 2]
Phase 2 trial evaluating EGFR-TKI with concurrent or sequential chemotherapy in patients with lung adenocarcinoma harboring EGFR activating …
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma [Phase 2]
Phase 2 trial of anetumab ravtansine for mesothelin-expressing lung adenocarcinoma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2019-04-05Clinical Trial Update: Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene [Phase 2]
Phase 2 clinical trial investigating bevacizumab with radiotherapy for oligometastasis in lung adenocarcinoma with negative driver gene muta…
-
CLINICAL_TRIALS withdrawal · 2019-02-04Clinical Trial Update: Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas
The clinical trial investigating neurotensin receptor expression in metastatic lung adenocarcinomas has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib [Phase 1, Phase 2]
Phase 1/2 trial assessing the combination of ruxolitinib and erlotinib in EGFR-mutant lung adenocarcinoma with acquired resistance to erloti…
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. [Phase 2]
Phase 2 trial of metformin combined with paclitaxel/carboplatin/bevacizumab in non-small cell lung cancer (lung adenocarcinoma) was terminat…
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: Sunitinib in Never-Smokers With Lung Adenocarcinoma [Phase 2]
Phase 2 trial evaluating sunitinib in never-smokers with lung adenocarcinoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-07-16Clinical Trial Update: Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma [Phase 3]
A Phase 3 trial compares icotinib to placebo as adjuvant therapy in EGFR-mutant lung adenocarcinoma; the trial status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2018-05-24Clinical Trial Update: Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) [Phase 2]
Phase 2 clinical trial update for poziotinib in stage IV lung adenocarcinoma with HER2 mutation (KASTT001) indicates the study has completed…
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations [NA]
Clinical trial update indicating completion and posting of results for a study on local therapies in oligometastatic non-small cell lung can…
-
CLINICAL_TRIALS research · 2018-04-03Clinical Trial Update: Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation [Phase 2]
Phase 2 clinical trial update evaluating gefitinib plus berberine as first-line therapy for EGFR-mutant lung adenocarcinoma.